Abstract Number: LB17 • ACR Convergence 2025
Circulating biomarkers for organ involvement in systemic lupus erythematosus: a series of systematic reviews and meta-analyses
Background/Purpose: Systemic lupus erythematosus (SLE) features heterogeneous clinical manifestations. The identification of biomarkers that facilitate initial disease recognition is a cornerstone of optimized clinical management.…Abstract Number: 2014 • ACR Convergence 2025
Efficacy and Safety of Firsekibart in Acute Gouty Arthritis Patients with eGFR < 60ml/min/1.73m2:A Post-Hoc Analysis of 24-Week Data
Background/Purpose: Approximately 70% of adults with gout have CKD (Chronic Kidney Disease) ≥stage 3 (i.e estimated glomerular filtration rate (eGFR) < 60ml/min/1.73m2), significantly restricts treatment…Abstract Number: 0650 • ACR Convergence 2025
Obinutuzumab Demonstrates Steroid-Sparing Effects and Consistent Benefit In Patients with Lupus Nephritis When Using Multiple Primary Endpoint Definitions: A Secondary Analysis of Phase III Trial Results
Background/Purpose: The Phase III REGENCY study (NCT04221477) demonstrated superiority of obinutuzumab (OBI) over placebo (PBO) in achieving complete renal response (CRR) at Week 76 when…Abstract Number: 1991 • ACR Convergence 2025
Co-Use of Mycophenolate Mofetil with Pegloticase Yielded Similar Clinical Outcomes as the Co-Use of Methotrexate
Background/Purpose: Pegloticase significantly reduces serum uric acid (sUA) values in patients with refractory gout. Co-use of methotrexate (MTX) improves efficacy and safety of pegloticase by…Abstract Number: 0638 • ACR Convergence 2025
Prevalence of lupus nephritis, end stage kidney disease, avascular necrosis, and mortality in systemic lupus erythematosus in the recent era
Background/Purpose: Systemic lupus erythematosus (SLE) is an autoimmune disease associated with an increased risk of chronic kidney disease (CKD), avascular necrosis (AVN), and mortality. Despite…Abstract Number: 1841 • ACR Convergence 2025
Differential metabolomic signatures along lupus nephritis spectrum
Background/Purpose: Lupus nephritis (LN) is a common feature in systemic lupus erythematosus (SLE) affecting up to 50% of the individuals with this disease. The gold…Abstract Number: 0615 • ACR Convergence 2025
Systemic Lupus Erythematosus Flares in Patients with End-Stage Kidney Disease on Renal Replacement Therapy or after Transplant
Background/Purpose: It has been observed that systemic lupus erythematosus (SLE) activity often goes into remission in patients with end-stage kidney disease (ESKD) on dialysis or…Abstract Number: 1835 • ACR Convergence 2025
Serum Zonulin As A Biomarker Of Renal Involvement In Systemic Lupus Erythematosus: Shedding Light On The Gut-Kidney Axis
Background/Purpose: Systemic lupus erythematosus (SLE) is a heterogeneous autoimmune disease in which lupus nephritis (LN) remains a major cause of morbidity and mortality. Zonulin, a…Abstract Number: 0856 • ACR Convergence 2025
Integrated Single-Cell and Spatial Transcriptomics Reveal Vascular and Immune Pathogenesis in APS Nephropathy
Background/Purpose: To elucidate the molecular and cellular mechanisms underlying antiphospholipid antibody (aPL) nephropathy using integrated single-cell and spatial transcriptomic (SP) profiling of kidney tissues.Methods: Renal…Abstract Number: 1768 • ACR Convergence 2025
TREM-1 and TREM-2 Define Inflammatory and Protective Axes in ANCA-Associated Glomerulonephritis
Background/Purpose: ANCA-associated vasculitis (AAV) is a small-vessel vasculitis that can lead to life-threatening renal injury. Neutrophils, monocytes and macrophages play a pivotal role not only…Abstract Number: 0838 • ACR Convergence 2025
Complete Renal Response and Long-Term, Progression-Free Survival in Adult Patients With Lupus Nephritis: A Retrospective Cohort Study in the United States
Background/Purpose: Complete renal response (CRR) and flare prevention, as early markers of long-term kidney survival, are important outcomes in lupus nephritis (LN) clinical trials.Methods: This…Abstract Number: 1722 • ACR Convergence 2025
Defining Safe Hydroxychloroquine Blood Levels: Time to Switch to Precision Monitoring for Optimized Lupus Care
Background/Purpose: Current guidelines recommend using hydroxychloroquine (HCQ) dose ≤5.0 mg/kg for managing SLE. However, 6-fold higher SLE flares, including those requiring hospitalizations, are noted with…Abstract Number: 1707 • ACR Convergence 2025
Racial and Ethnic Disparities in Kidney Transplant Outcomes Among Patients With Systemic Lupus Erythematosus (SLE): A 20-Year Analysis Spanning Before and After the 2014 Kidney Allocation System Revision
Background/Purpose: Systemic lupus erythematosus (SLE) is a leading cause of end-stage kidney disease (ESKD) in young women, particularly among racial and ethnic minorities. Kidney transplantation…Abstract Number: 1546 • ACR Convergence 2025
Tacrolimus Versus Voclosporin for Active Lupus Nephritis: A Comparative Meta-analysis of Renal Response
Background/Purpose: Lupus nephritis (LN) is seen in approximately 40–60 % of patients with systemic lupus erythematosus (SLE) and contributes significantly to morbidity and mortality in…Abstract Number: PP08 • ACR Convergence 2025
Living Well Despite the Challenges of Sjögren’s Disease and Systemic Lupus Erythematous: My Perspective as a Health Care Provider and Patient
Background/Purpose: Typically, the diagnosis of any autoimmune condition can be challenging and take years. In my case, my diagnosis of Sjögren's disesase (SjD) was established…
- 1
- 2
- 3
- …
- 10
- Next Page »